QUESTION 1:
What is the expected diagnostic yield for vestibular schwannomas when using a magnetic resonance imaging (MRI) to evaluate patients with previously published definitions of asymmetric sensorineural hearing loss? TARGET POPULATION: These recommendations apply to adults with an asymmetric sensorineural hearing loss on audiometric testing. RECOMMENDATION: Level 3: On the basis of an audiogram, it is recommended that MRI screening on patients with ≥10 decibels (dB) of interaural difference at 2 or more contiguous frequencies or ≥15 dB at 1 frequency be pursued to minimize the incidence of undiagnosed vestibular schwannomas. However, selectively screening patients with ≥15 dB of interaural difference at 3000 Hz alone may minimize the incidence of MRIs performed that do not diagnose a vestibular schwannoma. QUESTION 2: What is the expected diagnostic yield for vestibular schwannomas when using an MRI to evaluate patients with asymmetric tinnitus, as defined as either purely unilateral tinnitus or bilateral tinnitus with subjective asymmetry? TARGET POPULATION: These recommendations apply to adults with subjective complaints of asymmetric tinnitus. RECOMMENDATION: Level 3: It is recommended that MRI be used to evaluate patients with asymmetric tinnitus. However, this practice is low yielding in terms of vestibular schwannoma diagnosis (<1%). QUESTION 3: What is the expected diagnostic yield for vestibular schwannomas when using an MRI to evaluate patients with a sudden sensorineural hearing loss? TARGET POPULATION: These recommendations apply to adults with a verified sudden sensorineural hearing loss on an audiogram. RECOMMENDATION: Level 3: It is recommended that MRI be used to evaluate patients with a sudden sensorineural hearing loss. However, this practice is low yielding in terms of vestibular schwannoma diagnosis (<3%).
The full guideline can be found at: https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_2. www.neurosurgery-online.com ABBREVIATIONS: ASNHL, asymmetric sensorineural hearing loss; dB, decibels; JGC, Joint Guidelines Committee; MRI, magnetic resonance imaging; SSNHL, sudden sensorineural hearing loss; VS, vestibular schwannoma D espite considerable evolution in the methods of vestibular schwannoma (VS) management over the past century, the optimal screening strategy for patients suspected of having a tumor remains unclear. The sensitivity of contrast-enhanced high-resolution magnetic resonance imaging (MRI) to detect retrocochlear pathology and the wide availability of this modality in the present day have led to it becoming the standard for VS identification. 1 However, knowing when an MRI is indicated can be challenging in the absence of clear neurological deficits. Additionally, rising healthcare costs have inspired analysis of resource utilization in a variety of different settings where screening tests are traditionally employed. [2] [3] [4] Undoubtedly, indiscriminate screening for VSs would have unfavorable financial ramifications given the rarity of these tumors, yet, a widely accepted, symptom-based screen to identify patients "at risk" for VS diagnosis continues to be elusive.
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_2) and in the methodology (https://www.cns.org/guidelines/guidelines-managementpatients-vestibular-schwannoma/chapter_1) article of this guideline series. The authors collaborated with a medical librarian to search for articles published from January 1, 1990 to December 31, 2014. Three electronic databases, PubMed, EMBASE, and Web of Science, were searched. A total of 806 citations were manually reviewed by the task force. The authors supplemented searches of electronic databases with manual screening of the bibliographies of all retrieved publications. The authors went to great lengths to obtain a complete set of relevant articles to ensure that the guideline is not based on a biased subset of articles. The selected studies were classified according to criteria for evidence on diagnosis as detailed in the Joint Guidelines Committee (JGC) guideline development methodology (https://www.cns.org/guidelines/ guideline-procedures-policies/guideline-development-methodology).
RESULTS
A total of 806 studies were screened and assessed for eligibility per the previous criteria, and 17 publications were included in the final review. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Using these studies, this guideline sought to evaluate audiometric definitions of interaural asymmetry in pure tone audiometry, the utility of asymmetric tinnitus as a screening tool by analyzing both the association of asymmetric tinnitus in the general population with the diagnosis of a VS and the frequency with which tumor patients retrospectively reported asymmetric tinnitus at the time of their presentation, and the utility of sudden sensorineural hearing loss (SSNHL) as a screening tool for VS by analyzing both the likelihood of patient presentation with an SSNHL and the frequency with which patients ultimately diagnosed with a tumor reported an SSNHL at the time of their presentation. Regarding the audiometric definitions of interaural asymmetry in pure tone audiometry, evidence suggests that for the diagnosis of a VS, the most sensitive, current audiometric definition of asymmetric sensorineural hearing loss (ASNHL) is ≥10 dB at 2 or more contiguous frequencies; or ≥15 dB at any single frequency. However, the criterion with the highest positive predictive value defines asymmetry as ≥15 dB interaural asymmetry at 3000 Hz. Regarding the use of asymmetric tinnitus as a screening tool, there were 720 patients subjected to MRI screening on the basis of asymmetric tinnitus in the absence of asymmetric hearing loss. The prevalence of asymmetric tinnitus as an initial presenting symptom among patients with a VS was <1%. However, many patients with a VS diagnosis reported asymmetric tinnitus, irrespective of other symptoms. Out of 584 tumors from studies that met inclusion criteria, 319 patients (54.6%) experienced asymmetric tinnitus. When considering these findings, it would appear that asymmetric tinnitus may correlate more with asymmetric hearing loss, in general, rather than the presence of a tumor. Based on available data, the presence of asymmetric tinnitus is a relatively unreliable screening tool for VS. Regarding the use of SSNHL as a screening tool for VS diagnosis, 54 tumors were found out of 1007 patients screened, suggesting that SSNHL is a presenting sign for a VS in approximately 5.4% of cases. When considering VS patients who have a documented history of SSNHL, 133 patients out of 1680 were identified, suggesting that 7.9% of tumor patients experienced SSNHL prior to their diagnosis. Based on available studies, SSNHL is a more reliable indicator of the presence of a VS than asymmetric tinnitus in the absence of an associated ASNHL.
DISCUSSION AND CONCLUSION
Although a variety of different studies have evaluated the optimal screening methods for VS, no perfect method exists. The existing literature on the expected VS patient symptom profiles suggests that as long as objective audiometric criteria are the basis of any screening protocol for VS, a portion of tumors will always go undiagnosed. Clearly, the most sensitive screening paradigm based on interaural audiometric threshold asymmetry, asymmetric tinnitus, and ASNHL would incorporate the least stringent of all of these criteria. In other words, MRI screening would be offered to any patient presenting with subjectively asymmetric tinnitus and/or a measurable SSNHL and/or an interaural asymmetry of ≥10 dB at 2 or more frequencies; or ≥15 dB at any single frequency, and it would be expected that this method would have the highest likelihood of diagnosing the greatest number of VSs while also providing the lowest likelihood of missing an opportunity for VS diagnosis. Yet, considering only the conflict example presented in the first recommendation, this increase in sensitivity would come at the expense of specificity, leading to a large number of negative MRI scans, and thus, a less efficient utilization of resources. Although the scope of this guideline was limited to audiometric screening and subjective tinnitus, it stands to reason that the most comprehensive criteria for VS screening would involve multiple features, both in terms of a patient's symptoms, audiologic testing, and their audiologic history (eg, noise exposure). Research directed towards the development of a weighted "score" for VS diagnosis will be a welcome addition to this body of literature.
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